Back to search
Neovascular (Wet) Age-Related Macular Degeneration
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Neovascular (Wet) Age-Related Macular Degeneration trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Neovascular (Wet) Age-Related Macular Degeneration trials you may qualify forResearchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as af…
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as af…
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-…
Study Design This is a Single-center, Phase I/II placebo-controlled study to assess the safety and efficacy of PRL3-zumab in patients with Neovascular Age-relat…
ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (…
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of this research study is to test whether a personalised care approach improves adherence compared to standard care. Many patients with macular dise…
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-re…